Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyclothiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyclothiazide SCHEMBL27178 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL29363642 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL8051136 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL8065909 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL1819665 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL5450863 | 0.89 | CHRM1 (0.79) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL10380303 | 0.88 | CHRM1 (0.77) | CHRM1ADRA1ACA7TDP1LMNA | |
| Polythiazide SCHEMBL6929926 | 0.87 | CHRM1 (0.76) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methalthiazide SCHEMBL28279774 | 0.87 | CHRM1 (0.76) | CHRM1ADRA1ACA7TDP1LMNA | |
| SCHEMBL14394546 | 0.86 | CHRM1 (0.75) | CHRM1ADRA1ACA7TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7690 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| US-12521402-B2 | Biomarker and drug combinations for heart failure prediction | Endothelium Scanning Nanotechnology Limited (AU) | 2026-01-13 | — | — | US | claimed |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2026-01-01 | — | — | US | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| US-20250281447-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | ANAVEX LIFE SCIENCES CORP. | 2025-09-11 | — | — | US | claimed |
| US-12280034-B2 | Sigma-1 receptor agonist systolic blood pressure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2025-04-22 | — | — | US | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-12203941-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | ASTUTE MEDICAL, INC. (US) | 2025-01-21 | — | — | US | claimed |
| US-12121509-B2 | Methods of improving renal function | CHINOOK THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | claimed |
| EP-0049505-A2 | Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | claimed |
| EP-0046289-A2 | Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | claimed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | claimed |
| US-4238485-A | 1,2,5-THIADIAZOLE DERIVATIVE, THIAZIDE DIURETIC, HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1980-12-09 | — | — | US | claimed |
| US-4217347-A | MERCAPTOALKYL ALKANOYLPROLINES AND A DIURETIC | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | claimed |
| US-4178374-A | SUBSTITUTED 1,2,5-THIADIAZOLE B-ADRENERGIC BLOCKING AGENT, PYRAZINE AND/OR THIAZIDE DIURETIC, TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 1979-12-11 | — | — | US | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |
| US-4005198-A | Treatment of acne vulgaris | Van Aman, Robert H. (US) | 1977-01-25 | — | — | US | claimed |